First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Trial Details

NCT ID
NCT07332455
Phase
PHASE1 / PHASE2
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • GSK5471713
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • Los Angeles, California, United States|34.05223,-118.24368
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • West Valley City, Utah, United States|40.69161,-112.00105

Key Eligibility Criteria

  • Participants with mCRPC that have histologically or cytologically confirmed adenocarcinoma of the prostate.
  • Participants with mCRPC that has prostate cancer progression while on Androgen deprivation therapy (ADT).
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 and life expectancy of ≥3 months (≥12 weeks).
  • Progression on ADT and \>=1 prior Androgen receptor pathway inhibitors (ARPI) for Hormone-Sensitive Prostate Cancer (HSPC) or Castration resistant …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →